Industry Press Releases

Altasciences and WuXi AppTec establish a collaboration for WIND projects

Friday, May 17, 2019

Altasciences, a medium-sized CRO specializing in a flexible, innovative approach to delivering comprehensive drug development from the selection of key candidates to proof of concept, announced today that it has signed an agreement to assist WuXi AppTec's Investigational New Drug (WIND) platform. WIND combines top-level CRO services and management of cross-functional programs and global regulatory experience to support IND applications. At WuXi Clinical, the CRO clinical arm of WuXi AppTec, will have the responsibility to manage the collaboration and guarantee a seamless experience.

Altasciences will provide its comprehensive service solutions, including clinical pharmacology, first-in-human and proof-of-concept clinical studies, program management, drafting of medical texts, biostatistics and data management to support and conduct initial phase clinical services complete for WuXi AppTec's various current WIND programs.

The original text of this announcement, written in the source language, is the official version that is authentic. The translations are offered solely for the reader's convenience and must refer to the text in the original language, which is the only legally valid one.

Contacts
Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com


Source: businesswire.com

Other Press Releases